CD8A and neuroblastoma: Similar strategies have been employed for treating neuroblastoma by natural killer cells,17, 42 and for facilitating cross-presentation of tumour antigens by Vγ9/Vδ2 T cells to CD8+ T cells.43 The relatively weak efficacy of anti-GD2 antibodies may have been due to the variable and often low expression of CD16 on the expanded Vγ9/Vδ2 T cells used in those assays.